Catalyst Pharmaceuticals

$3.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.21 (+6.02%) Today
-$0.01 (-0.23%) As of 5:00 PM EST after-hours

Why Robinhood?

You can buy or sell CPRX and other stocks, options, and ETFs commission-free!

About CPRX

Catalyst Pharmaceuticals, Inc. Common Stock, also called Catalyst Pharmaceuticals, is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL. The listed name for CPRX is Catalyst Pharmaceuticals, Inc. Common Stock.

CEO
Patrick J. McEnany
Employees
76
Headquarters
Coral Gables, Florida
Founded
2002
Market Cap
383.50M
Price-Earnings Ratio
5.51
Dividend Yield
Average Volume
1.46M
High Today
$3.72
Low Today
$3.53
Open Price
$3.53
Volume
1.13M
52 Week High
$5.28
52 Week Low
$2.55

Collections

CPRX Earnings

-$0.13
-$0.04
$0.04
$0.13
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 15, After Hours

You May Also Like